Stoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.The company reported quarterly losses of 93 cents per share which missed the analyst consensus estimate of losses of 80 cents per share. The company reported quarterly sales of $9.325 million which beat the analyst consensus estimate of $6.044 million.Stoke Therapeutics shares closed at $29.56 on Monday.These analysts made changes to their price targets on Stoke Therapeutics following earnings announcement.
Canaccord Genuity analyst Sumant Kulkarni maintained the stock with a Buy and lowered the price target from $60 to $58.
Wedbush analyst Laura Chico maintained the stock with an Outperform rating and raised the price target from $38 to $40.
